Investor Overview

Corporate Profile
 

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis' core Epoch™ Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive™ robotic navigation system and consumables, which have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

FINANCIAL NEWS
05/29/19
ST. LOUIS , May 29, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to present at the 9th Annual LD Micro

Copyright West LLC. Minimum 15 minutes delayed.

RECENT FILINGS

Filing date Form
4
4
4
4
Receive E-mail Alerts
 
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Investor Presentation
Investor Contacts
 
Martin Stammer
Chief Financial Officer
Stereotaxis, Inc.
investors@stereotaxis.com
© Copyright Stereotaxis 2019